Support Alert

Class 2 Medicines Recall: Various Marketing Authorisation Holders and parallel distributor companies, Irbesartan-containing products

Specific batches of products are being recalled by the Marketing Authorisation Holders and parallel distributor companies as a precautionary measure due to contamination with an impurity called 5-(4’-(azidomethyl)-[1,1’-biphenyl]-2yl)-1H-tetrazole, which has mutagenic potential. These batches are being recalled as the level of contamination is above the acceptable limit.

Further information including details of the affected products and batches, a brief description of the problem and advice for healthcare professionals can be found on the MHRA website.


Renew for 2022

Your dedication to patient care has made us proud during 2021.

That's why you can count on us to represent your interests and support your efforts every step of the way in 2022.